Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
Amid continued advances in oncology research, the renal cancer pipeline reflects growing efforts to address the rising global burden of the disease. In 2022, an estimated 434,840 new cases of kidney cancer were diagnosed worldwide, highlighting the need for more effective therapies. Renal cancer pipeline analysis by Expert Market Research indicates a strong clinical focus on targeted therapies, immunotherapies, and novel combination regimens designed to improve survival outcomes, overcome therapeutic resistance, and expand treatment options for patients with advanced disease.
-
Major companies involved in the renal cancer pipeline analysis include HiberCell, Inc., Zhejiang Haichang Biotech Co., Ltd., and others.
-
Leading drugs currently in the pipeline include BMS-986506, DEG6498, and others.
-
The renal cancer pipeline is driven by advances in precision oncology, expanding immunotherapy combinations, targeted protein degradation technologies, and increasing investment in novel therapeutics aimed at improving survival and overcoming treatment resistance.
Report Coverage
The Renal Cancer Pipeline Analysis Report by Expert Market Research gives comprehensive insights into renal cancer therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for renal cancer. The renal cancer report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The renal cancer pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with renal cancer treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to renal cancer.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Renal Cancer Pipeline Outlook
The renal cancer pipeline continues to expand with increasing emphasis on precision oncology, next-generation immunotherapies, and targeted therapies. Clinical development is advancing across multiple phases, with a strong concentration of candidates in Phase 2, reflecting sustained innovation. Regulatory momentum is also strengthening, highlighted by the June 2026 FDA approval of Welireg (belzutifan) plus Keytruda (pembrolizumab) as adjuvant therapy for eligible patients with clear cell renal cell carcinoma following nephrectomy. This milestone is expected to accelerate further investment, combination therapy development, and biomarker-driven strategies, supporting improved long-term outcomes and broadening future treatment options for renal cancer patients.
Renal Cancer Epidemiology
renal cancer (predominantly renal cell carcinoma) accounted for 434,840 new cases and 155,953 deaths worldwide in 2022, with incidence consistently higher in men than women. The disease burden is greatest in high-income regions, where age-standardized incidence rates reach 12.6 per 100,000 men, compared with 1.6 per 100,000 in low-HDI countries. Projections indicate global renal cancer cases could increase by 72%, reaching approximately 745,791 new cases by 2050, driven by population aging, obesity, hypertension, smoking, and improved diagnostic practices.
Renal Cancer – Pipeline Therapeutic Assessment
This section of the report covers the analysis of renal cancer drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
The renal cancer pipeline analysis report covers 50+ drug analyses based on drug classes:
- Small Molecules
- Monoclonal Antibodies
- Cell Therapies
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration:
- Oral
- Parenteral
- Others
Renal Cancer Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total renal cancer clinical trials. Phase 1 (35.94%), Phase 3 (10.04%), Early Phase 1 (3.35%), and Phase 4 (2.01%). This phase-wise distribution reflects a robust clinical pipeline, with a strong emphasis on mid-stage development and continued advancement of innovative renal cancer therapies.
Renal Cancer Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the renal cancer pipeline analysis include small molecules, monoclonal antibodies, and cell therapies. The renal cancer report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for renal cancer. Small molecules constitute a significant share of the pipeline, targeting key molecular pathways involved in tumor growth and progression. For instance, DEG6498, a small-molecule molecular glue degrader, is being developed to selectively degrade the RNA-binding protein HuR, offering a novel therapeutic approach for advanced renal cancer.
Renal Cancer Clinical Trials – Key Players
The EMR report for the renal cancer pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed renal cancer therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in renal cancer clinical trials:
- Merck Sharp & Dohme LLC
- Degron Therapeutics Co.
- Bristol-Myers Squibb
- Telix Pharmaceuticals (Innovations) Pty Limited
- HiberCell, Inc.
- Zhejiang Haichang Biotech Co., Ltd.
- Servier Bio-Innovation LLC
- Imbioray (Hangzhou) Biomedicine Co., Ltd.
- Hrain Biotechnology Co., Ltd.
- Sichuan Baili Pharmaceutical Co., Ltd.
- Neomorph, Inc.
- Hoffmann-La Roche
Renal Cancer – Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for renal cancer. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of renal cancer drug candidates.
Drug: DEG6498
DEG6498 is an investigational small-molecule molecular glue degrader developed by Degron Therapeutics Co. for advanced solid tumors, including renal cancer. The orally administered candidate selectively degrades the RNA-binding protein HuR, disrupting oncogenic signaling pathways involved in tumor growth, survival, and metastasis. By reducing HuR expression, DEG6498 aims to inhibit cancer cell proliferation and enhance antitumor activity in renal cancer. The ongoing Phase I study is expected to be completed in May 2028. Degron Therapeutics specializes in targeted protein degradation technologies to develop innovative precision oncology therapies.
Drug: BMS-986506
BMS-986506 is an investigational small-molecule targeted therapy being developed by Bristol-Myers Squibb for advanced clear cell renal cell carcinoma. The first-in-human agent is designed to inhibit a novel molecular target involved in renal cancer progression, offering a potential treatment option for patients previously treated with immune checkpoint inhibitors and VEGF-targeted therapies. The Phase I/Ib trial is expected to reach study completion in April 2031. Bristol Myers Squibb is a global biopharmaceutical leader with a strong oncology portfolio spanning immunotherapies, targeted therapies, and precision medicines.
Drug: WGI-0301 + Nivolumab
WGI-0301 plus Nivolumab is an investigational small-molecule and monoclonal antibody combination immunotherapy being developed by Zhejiang Haichang Biotech Co., Ltd. for advanced renal cell carcinoma. WGI-0301 is administered with the PD-1 inhibitor nivolumab to enhance antitumor immune responses, aiming to improve objective response rates and overcome resistance to immunotherapy. The Phase II clinical trial is expected to be completed in September 2028. Zhejiang Haichang Biotech focuses on innovative oncology drug development, emphasizing novel targeted therapies and immuno-oncology combinations.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
Key Questions Answered in the Renal Cancer Pipeline Insight Report
- Which companies/institutions are leading the renal cancer drug development?
- Which company is leading the renal cancer pipeline development activities?
- What is the current renal cancer commercial assessment?
- What are the opportunities and challenges present in the renal cancer pipeline landscape?
- What is the efficacy and safety profile of renal cancer pipeline drugs?
- Which company is conducting major trials for renal cancer drugs?
- Which companies/institutions are involved in renal cancer collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in renal cancer?
Reasons To Buy This Report
The Renal Cancer Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for renal cancer. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into renal cancer collaborations, regulatory environments, and potential growth opportunities.
Related Reports
Pricing Plans
Upto 15% Off
USD
-
$1999 $1799
-
$3099 $2789
-
$4599 $3909
-
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
